CDNA (CareDx, Inc.) יחס שווי שוק לשווי בספרים
CareDx, Inc (CDNA) relies on external providers for logistics and cloud services, maintaining a moderate level of dependency. Demand for its transplant monitoring services is not subject to market cycles, rendering the asset defensive, with the current indicator standing at 8.39. A monopoly within a narrow diagnostic segment guarantees high profitability, as evidenced by the company's price chart on the GURU.Markets platform.
%20-%20%D7%99%D7%97%D7%A1%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_CDNA_-_CareDx-Inc_-_Market-Cap-to-Net-Assets-Ratio "CDNA יחס שווי שוק לערך בספרים CareDx, Inc (04.07.2022 - 27.10.2026) | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור caredx.com (CDNA)
CareDx, Inc (CDNA) possesses high scientific and technological potential in the field of transplant DNA analysis, creating significant intangible value that often exceeds the net assets recorded in financial statements. By analyzing the history of market valuation relative to book value, an investor can determine the market premium over equity, enabling the timely detection of either a fundamental weakening of the issuer or an undervaluation of its innovative resources.